Literature DB >> 10049962

Once- versus twice-daily gentamicin dosing in neonates >/=34 Weeks' gestation: cost-effectiveness analyses.

P J Thureen1, P D Reiter, A Gresores, N M Stolpman, K Kawato, D M Hall.   

Abstract

OBJECTIVES: To compare performance and cost analysis of two gentamicin regimens in infants >/=34 weeks' gestation requiring antibiotics for a 72-hour rule-out sepsis evaluation. A once-daily dosing (ODD) regimen of 4 mg/kg was compared with a standard twice-daily dosing (TDD) regimen of 2.5 mg/kg every 12 hours. SETTING AND
DESIGN: Infants at two university-affiliated Level III nurseries were prospectively temporally allocated to receive ODD (n = 27) or TDD (n = 28) as part of their 72-hour empirical antibiotic regimen. Performance of dosing regimens was based on target serum gentamicin concentrations (SGC) established prospectively as a peak of 5 to 10 microgram/mL and a trough of </=2 microgram/mL. SGC were determined by fluorescence polarization immunoassay on day 3 of therapy. Cost data were obtained by distributing a questionnaire to 15 pediatric pharmacy practice sites. Inquiries were made regarding hospital cost of drug acquisition, drug supplies, drug preparation and administration, and serum concentration analysis. Performance and cost data were then used to do a cost-effectiveness analysis.
RESULTS: Mean peak concentrations were higher with ODD (7.9 +/- 0.2 microgram/mL) than TDD (6.7 +/- 0.3 microgram/mL). Half of the patients in the TDD group had trough concentrations >2 microgram/mL, compared with none in the ODD group. Overall, 57% of the SGCs in the TDD group were outside the target concentration range versus 7% in the ODD group. Based on questionnaire results, a total 72-hour process cost of ODD versus TDD was compared for regimens with and without use of SGC analysis. If SGCs are obtained, more than 75% of the cost associated with gentamicin therapy is attributable to SGC analysis. Based on a cost-effectiveness analysis, ODD was the dominant dosing strategy in all categories analyzed.
CONCLUSIONS: ODD of gentamicin at 4 mg/kg in neonates >/=34 weeks' gestation is the preferable treatment strategy based on: 1) significantly improved SGC performance compared with TDD; 2) elimination of the need for routine SGC collection in infants on short courses of therapy; and 3) significant antibiotic-associated hospital cost savings when compared with conventional therapy of TDD and SGC analysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10049962     DOI: 10.1542/peds.103.3.594

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  21 in total

1.  A randomised, controlled trial of once daily and multi-dose daily gentamicin in young Kenyan infants.

Authors:  M English; S Mohammed; A Ross; S Ndirangu; G Kokwaro; F Shann; K Marsh
Journal:  Arch Dis Child       Date:  2004-07       Impact factor: 3.791

2.  The effect of sepsis upon gentamicin pharmacokinetics in neonates.

Authors:  M Lingvall; D Reith; R Broadbent
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

3.  Extended-interval gentamicin dosing in achieving therapeutic concentrations in malaysian neonates.

Authors:  Yee Shan Low; Sin Li Tan; Angeline Sl Wan
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

Review 4.  One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.

Authors:  Shripada C Rao; Ravisha Srinivasjois; Kwi Moon
Journal:  Cochrane Database Syst Rev       Date:  2016-12-06

5.  Accuracy of empiric gentamicin dosing guidelines in neonates.

Authors:  Anna E Hitron; Yao Sun; Sarah B Scarpace
Journal:  J Pediatr Pharmacol Ther       Date:  2010-10

6.  Pharmacological differences between once daily and twice daily gentamicin dosage in newborns with suspected sepsis.

Authors:  Inge Hagen; Knut Øymar
Journal:  Pharm World Sci       Date:  2008-11-04

7.  Gentamicin usage in newborns--a simple and practical regime.

Authors:  Monika Bajaj; Katherine Palmer
Journal:  Pharm World Sci       Date:  2004-08

8.  High-dose gentamicin in newborn infants: is it safe?

Authors:  Jon Widding Fjalstad; Einar Laukli; John N van den Anker; Claus Klingenberg
Journal:  Eur J Pediatr       Date:  2013-11-14       Impact factor: 3.183

9.  High-Dose, Extended-Interval Gentamicin and Tobramycin for Pediatric Inpatients: A Survey of Canadian Hospital Pharmacists.

Authors:  Caitlin Roy; Carolyn Gray; Lisa Ruda; Ali Bell; Jennifer Bolt
Journal:  Can J Hosp Pharm       Date:  2016-10-31

Review 10.  Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries.

Authors:  Gary L Darmstadt; Mary Miller-Bell; Maneesh Batra; Paul Law; Kiely Law
Journal:  J Health Popul Nutr       Date:  2008-06       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.